Published in Curr Infect Dis Rep on February 01, 2001
Pharmacodynamic activity of telithromycin at simulated clinically achievable free-drug concentrations in serum and epithelial lining fluid against efflux (mefE)-producing macrolide-resistant Streptococcus pneumoniae for which telithromycin MICs vary. Antimicrob Agents Chemother (2005) 0.89
Population pharmacokinetic and pharmacodynamic modeling of norvancomycin. Eur J Clin Microbiol Infect Dis (2008) 0.82
Pharmacokinetics of sarafloxacin in allogynogenetic silver crucian carp, Carassius auratus gibelio. Fish Physiol Biochem (2015) 0.75
Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis (1998) 16.20
Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. N Engl J Med (1999) 10.06
Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother (1993) 7.05
Acute otitis media: management and surveillance in an era of pneumococcal resistance--a report from the Drug-resistant Streptococcus pneumoniae Therapeutic Working Group. Pediatr Infect Dis J (1999) 5.88
Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA (1998) 4.99
In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations. Antimicrob Agents Chemother (1998) 4.88
Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program. Clin Infect Dis (1998) 3.76
Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J (1996) 3.59
Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med (2000) 3.09
The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents. Clin Pharmacokinet (1995) 2.66
Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 U.S. Surveillance study. Antimicrob Agents Chemother (1999) 2.63
Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother (1998) 2.19
Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection. Antimicrob Agents Chemother (1999) 2.06
A multicentre collaborative study of the antimicrobial susceptibility of community-acquired, lower respiratory tract pathogens 1992-1993: the Alexander Project. J Antimicrob Chemother (1996) 1.99
Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae. J Antimicrob Chemother (1999) 1.73
Pharmacokinetics and pharmacodynamics of fluoroquinolones. Drugs (1999) 1.55
Prevalence of antimicrobial resistance in respiratory tract isolates of Streptococcus pneumoniae: results of a Canadian national surveillance study. The Canadian Respiratory Infection Study Group. Antimicrob Agents Chemother (1999) 1.49
Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis. J Antimicrob Chemother (1997) 1.42
Activity of moxifloxacin, administered once a day, against Streptococcus pneumoniae in an in vitro pharmacodynamic model of infection. Antimicrob Agents Chemother (1999) 1.39
Efficacy of beta-lactam antibiotics: integration of pharmacokinetics and pharmacodynamics. Diagn Microbiol Infect Dis (1997) 1.13
Comparison of the fluoroquinolones based on pharmacokinetic and pharmacodynamic parameters. Pharmacotherapy (2000) 1.02
Pharmacodynamic principles of antimicrobial therapy in the prevention of resistance. Chest (1999) 1.02
Relevance of the Alexander Project: pharmacodynamic considerations. J Antimicrob Chemother (1996) 0.98
Pharmacodynamics and pharmacokinetics of levofloxacin. Chemotherapy (2000) 0.96
Pharmacokinetic contributions to postantibiotic effects. Focus on aminoglycosides. Clin Pharmacokinet (1994) 0.93
Pharmacodynamics to combat resistance. J Antimicrob Chemother (2000) 0.93
Increasing antibiotic resistance among otitis media pathogens and their susceptibility to oral agents based on pharmacodynamic parameters. Pediatr Infect Dis J (2000) 0.86
Antibacterial use in community practice: assessing quantity, indications and appropriateness, and relationship to the development of antibacterial resistance. Drugs (1999) 0.84
The new fluoroquinolones: A critical review. Can J Infect Dis (1999) 0.82
Subinhibitory antimicrobial concentrations: A review of in vitro and in vivo data. Can J Infect Dis (1992) 0.79
Comparative activities of ciprofloxacin and levofloxacin against Streptococcus pneumoniae in an In vitro dynamic model. Antimicrob Agents Chemother (2000) 0.75
Evolving patterns of resistance to respiratory pathogens in Canada. Can Respir J (1999) 0.75